Value Investor
Start free

Cooper Companies

COO on Nasdaq. Cooper sells contact lenses and surgical products to eye care and women’s health providers. Market value $10.8bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to July 2026. Quality checks use five annual reports, the latest for the year to October 2025.

Should I look at this?

Worth a closer look

Why it could be worth it

What to watch out for

Nothing stood out in the numbers we check.

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to July 2026
6.3%high

For every $100 of what the whole company costs, it produced $6.28 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to July 2026
24.2×full

You pay 24.2 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to October 2025
4.8%five-year median

Each dollar kept in the business earns 5 cents a year. Above 10 is good.

Quality score: 86 of 100. Price score: 73 of 100. Our list needs 70 on quality and 60 on price.

$56.77 a share, 11% above its 1-year low

Over the past year the price has ranged from $51.01 to $89.83.

Pays no dividend

Prices from Monday’s close (5 October).

Five years of cash, in billions

0.5
0.5
0.2
0.3
0.4
0.7
2021202220232024202512 monthsto Jul '26

Spare cash swings from quarter to quarter here: $678 million in the past 12 months, $434 million in the year to October 2025.

Revenue
$2.9bn$3.3bn$3.6bn$3.9bn$4.1bn
Operating margin
17.3%15.3%14.8%18.1%16.7%
Debt to equity
0.210.390.340.320.30
Shares outstanding
0.05bn0.05bn0.20bn0.20bn0.19bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Nothing unusual
  • Financial strength (Piotroski)7 of 9
  • Profit backed by cash (accruals)Yes
  • Debt0.30× equity
  • Revenue growth, five yearsStrong, 11.0% a year
  • Buying back its own sharesNo, 285% more shares since 2021

The quarter to July 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $1.1 billion last quarter, about the same as a year ago.
  • Profit: $433 million, up 340% on a year ago.
  • It keeps 13 cents of each $1 of sales as operating profit, down from 18 cents a year earlier.
  • Spare cash over the past 12 months: $678 million, up from $412 million.
  • 3% fewer shares than a year ago. Each share owns a bit more of the company.
  • Debt is $2.4 billion more than cash, about the same as a year ago.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
October 2024$1.0bn
January 2025$965m
April 2025$1.0bn
July 2025$1.1bn
October 2025$1.1bn
January 2026$1.0bn
April 2026$1.1bn
July 2026$1.1bn
Profit by quarter
Profit by quarter
Quarter toAmount
October 2024$118m
January 2025$104m
April 2025$88m
July 2025$98m
October 2025$85m
January 2026$131m
April 2026-$78m
July 2026$433m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
10 December 2026
Last annual report (10-K)
5 December 2025
Next quarterly (estimated, 10-Q)
9 December 2026

Who owns it

15 long-term investors we follow own it, up from 11 last quarter. 675 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

2 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 7 insiders bought $3m of shares on the open market.

Cluster buy3 insiders bought within 30 days (11 September 2026 to 16 September 2026).
  • Kurzius Lawrence Erik
    Director
    Bought
    Date
    16 September 2026
    Shares
    10,000
    Price
    $54.93
    Value
    $549,320
  • Rosebrough Walter M Jr
    Director
    Bought
    Date
    14 September 2026
    Shares
    3,000
    Price
    $54.29
    Value
    $162,870
  • Kurzius Lawrence Erik
    Director
    Bought
    Date
    14 September 2026
    Shares
    10,000
    Price
    $53.91
    Value
    $539,150
  • Keel Paul A
    Director
    Bought
    Date
    11 September 2026
    Shares
    4,701
    Price
    $53.18
    Value
    $250,000
  • Rosebrough Walter M Jr
    Director
    Bought
    Date
    11 September 2026
    Shares
    7,000
    Price
    $54.11
    Value
    $378,770
  • Lucchese Cynthia L
    Director
    Bought
    Date
    22 December 2025
    Shares
    1,784
    Price
    $84.06
    Value
    $149,963
  • Rivas Maria
    Director
    Bought
    Date
    18 December 2025
    Shares
    1,000
    Price
    $82.13
    Value
    $82,130
  • Kurzius Lawrence Erik
    Director
    Bought
    Date
    17 December 2025
    Shares
    2,000
    Price
    $82.50
    Value
    $165,000
  • Sheffield Holly R
    President, CSI
    Bought
    Date
    16 December 2025
    Shares
    1,230
    Price
    $80.75
    Value
    $99,323
  • White Albert G III
    President & CEO, Director
    Bought
    Date
    16 December 2025
    Shares
    10,000
    Price
    $80.80
    Value
    $808,000

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 5 Dec 2025, plus the 10-Q filed 9 Sep 2026 and 8 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • Economic and trade sanctions, including tariff and import/export regulations by the U.S. and foreign governments, could make it more difficult or costly for us to conduct our operations or achieve our business objectives.

    Could happen
    Changes in import and export policies, including new, increased or retaliatory tariffs, sanctions and countersanctions and customs restrictions by the U.S. and foreign governments, may disrupt our supply chain, adversely affect our relationships with customers and impact our competitiveness. It may be time-consuming and expensive for us to alter our business operations to adapt to or comply with any such changes. If we are unable to effectively manage these risks, our business, financial condition and results of operations could be materially and adversely affected.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.